| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9872176 | International Journal of Radiation Oncology*Biology*Physics | 2005 | 9 Pages |
Abstract
Conclusions: Our results suggest that Ad-E2F-1 significantly enhances the response of p53wild-type and p53null prostate cancer cells to radiation therapy, although radiosensitization is more pronounced in the presence of p53. Ad-E2F-1 may be a useful adjunct to radiation therapy in the treatment of prostate cancer.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Khanh H. M.D., Paul B.S., Li-Yan M.D., Naji M.D., Kelly K. M.D., Peter R. Ph.D., Alan M.D., Ph.D.,